What is SilcsBio?
SilcsBio operates at the intersection of high-performance computing and medicinal chemistry, providing specialized computer-aided drug design (CADD) solutions. Its core technology, including the SILCS and CGenFF platforms, enables researchers to generate high-resolution 3D free energy maps. These analytical tools are critical for identifying viable drug targets and refining lead compounds, effectively reducing the time-to-market for novel therapeutics. By offering both software licensing and expert consultation, SilcsBio serves as a vital partner for biotechnology firms and pharmaceutical enterprises aiming to mitigate the high costs and risks associated with traditional drug discovery pipelines.
How much funding has SilcsBio raised?
SilcsBio has raised a total of $1.3M across 1 funding round:
Other Financing Round
$1.3M
Other Financing Round (2016): $1.3M with participation from National Institute of Health
Key Investors in SilcsBio
National Institute of Health
A premier public health research agency that provides critical funding and support for innovative biomedical technologies and scientific advancements.
What's next for SilcsBio?
With this major enterprise-level funding, SilcsBio is well-positioned to scale its operational capacity and expand its software capabilities. The strategic roadmap likely involves enhancing the SILCS-Biologics platform to address the growing demand for complex molecule development. As the industry shifts toward more data-driven, AI-augmented discovery models, SilcsBio's focus on rigorous biophysical accuracy provides a competitive moat. Future growth will likely center on deepening integration with existing pharmaceutical workflows and expanding its footprint in the global biotech ecosystem, ensuring that its computational tools remain at the forefront of modern drug development.
See full SilcsBio company page
